Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil

Udenafil is a phosphodiesterase‐5 inhibitor used to treat erectile dysfunction. Although udenafil is not predominantly eliminated by the kidney, renal impairment can alter its secretion/transport pathways. Drug pharmacokinetics and safety must therefore be assessed in subjects with a renal impairmen...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical pharmacology Vol. 58; no. 7; pp. 905 - 912
Main Authors:	Cho, Yong‐Soon, Noh, Yook‐Hwan, Lim, Hyeong‐Seok, Cho, Sang‐Heon, Ghim, Jong‐Lyul, Choe, Sangmin, Kim, Soon‐Bae, Park, Jung‐Sik, Lee, Sang‐Koo, Yang, Won‐Seok, Chang, Jai‐Won, Bahng, Mi‐Young, Bae, Kyun‐Seop
Format:	Journal Article
Language:	English
Published:	England American College of Clinical Pharmacology 01-07-2018 Wiley Subscription Services, Inc
Subjects:	Creatinine Drug dosages Erectile dysfunction Impairment Pharmacokinetics Phosphodiesterase Phosphodiesterase‐5 Renal function Renal impairment Safety Secretion Udenafil Udenafil Renal impairment Safety Pharmacokinetics Phosphodiesterase-5
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!